MedTrace Logo

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

NCT00063570 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2009-05-29

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine if the two drugs can help patients feel better while causing the tumor to become smaller or disappear; evaluate the safety of giving both pemetrexed and gemcitabine in patients with advanced breast cancer.

Conditions

Interventions

DRUG

Pemetrexed

500 mg/m2, intravenous (IV), every 14 days, until disease progression

DRUG

Gemcitabine

1500 mg/m2, intravenous (IV), every 14 days, until disease progression

DRUG

Gemcitabine

1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression

DRUG

Pemetrexed

500 mg/m2, intravenous (IV), every 21 days, until disease progression

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00063570 on ClinicalTrials.gov